Adherence to postmenopausal hormone therapy during the year after the initial prescription: a population-based study

Article Abstract:

Women who use continuous combined hormone therapy less likely to stop than women who use sequential hormone therapy. Continuous hormone therapy is taken every day of the month whereas sequential hormone therapy is not. In a study of 204 women, 54% of those on sequential therapy quit after the first year compared to 69% of those taking continuous therapy.

Usage, Evaluation, Patient compliance

---

Continuous combined hormone replacement therapy and risk of endometrial cancer

Article Abstract:

Continuous combined hormone replacement therapy does no appear to increase the risk of endometrial cancer and may even decrease the risk. In this form of hormone therapy, women take both estrogen and a progestogen every day rather than taking them sequentially.

Health aspects, Risk factors

---

Dose of progestin in postmenopausal-combined hormone therapy risk of endometrial cancer

Article Abstract:

The impact of progestin dose on the risk of endometrial cancer is examined where results reveal that combination of progestin dose with hormone therapy appears to affect this risk. Among users of continuous combined hormone regimen, risk of endometrial cancer was low, regardless of medroxyprogesterone acetate dose.

United States, Causes of, Complications and side effects

Similar abstracts:

• Abstracts: Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. Group B streptococcal disease in the era of intrapartum antibiotic prophylaxis
• Abstracts: A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1-infected patients
• Abstracts: Effect of Estrogen on Brain Activation Patterns in Postmenopausal Women During Working Memory Tasks. Estrogen and Alzheimer Disease Plausible Theory, Negative Clinical Trial
• Abstracts: Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. Long-term outcome of fulminant myocarditis as compared with acute (nonfulminant) myocarditis
• Abstracts: Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.